Mateon Partners With WideTrial for Data-Generating Expanded Access Programs in Cancer
09. September 2019 08:30 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif. and SAN FRANCISCO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN), announced today that it has executed agreements with WideTrial Inc. for an Expanded...
Mateon Enters into Merger Agreement with PointR Data to Leverage Disruptive AI Technology in Its Innovation-Driven Quest for a Cure of Cancer
19. August 2019 09:15 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif. and SANTA CLARA, Calif., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) and PointR Data Inc. (PointR), a privately-held, developer of high...
Oncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced Pivotal Phase 3 Clinical Testing
30. Juli 2019 08:55 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative...
Internationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of Oncotelic
16. Juli 2019 10:31 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic"), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to development of innovative...
Oncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory Board
12. Juni 2019 08:30 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB: MATN) dedicated to development of innovative...
Mateon and Oncotelic Report on Continuing Integration of the two Businesses
10. Juni 2019 08:30 ET
|
Mateon Therapeutics
-Relocation of Corporate Headquarters -Introduction of Amit Shah as incoming CFO -Presentation of Integrated Pipeline at BIO2019 AGOURA HILLS, Calif., June 10, 2019 ...
Mateon Reports First Quarter 2019 Financial Results
15. Mai 2019 09:39 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline
25. April 2019 06:35 ET
|
Mateon Therapeutics
-Merger creates a publicly-traded clinical stage immuno-oncology company developing treatments for advanced cancers including aggressive brain tumors, pancreatic cancer, and melanoma -Phase 2...
Mateon Enters into Merger Agreement with Oncotelic
18. April 2019 06:01 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif. and AGOURA HILLS, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc., a privately-held, late clinical-stage cancer...
Mateon Therapeutics Reports Third Quarter 2018 Financial Results
14. November 2018 08:45 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...